Silverarc Capital Management, Llc Buys Fulcrum Therapeutics Inc, Cogent Biosciences Inc, Cerus Corp, Sells Chinook Therapeutics Inc, Dicerna Pharmaceuticals Inc, Macrogenics Inc

• New Purchases: FULC, ARVN, LPTX, ERAS, CYTK, LHDX, BIIB, CRNX, NTLA, PNT, CYBN, CABA, ISEE, KROS, XENE, ARCT, ADGI, CBIO,
• Added Positions: COGT, CERS, NXTC, IMTX, CLDX, MCRB, MRTX, VCYT, VRDN, ITOS, UTHR, SGEN, BLU, BHVN, AMYT, CYCC, VRAY, MRUS, SRRA, CALA, HZNP, VTGN, PYPD, AYLA, OTIC, BNTC,
• Reduced Positions: DRNA, RNLX, MORF, MSAC, CRIS, DNAB, DNAA, DNAD, DNAC, ADMS, AFMD, ELOX, IMGN, RAPT, EYPT, ZNTL, KURA, ITCI, EVGN, SURF, JNCE, HALO, ACRS, RACB, MREO, ARNA, STXS, HLXA, ATHA, INSM, GH, CGEN,
• Sold Out: KDNY, MGNX, VSTM, TCRR, ALDX, CGEM, MRSN, CERE, RLMD, RETA, DCTH, TRIL, WVE, AKRO, ARDX, ASND, ODT, SNDX, ETNB, SLRX, APLS, RCKT, KALV, MDNA, QURE, MDGL, FMTX, ETON, PHGE,

For the details of SILVERARC CAPITAL MANAGEMENT, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/silverarc+capital+management%2C+llc/current-portfolio/portfolio

1. Biohaven Pharmaceutical Holding Co Ltd (BHVN) - 61,897 shares, 4.86% of the total portfolio. Shares added by 9.31%
2. Veracyte Inc (VCYT) - 179,548 shares, 4.72% of the total portfolio. Shares added by 19.02%
3. Mirati Therapeutics Inc (MRTX) - 45,941 shares, 4.59% of the total portfolio. Shares added by 21.69%
4. Merus NV (MRUS) - 345,964 shares, 4.30% of the total portfolio. Shares added by 7.84%
5. Amryt Pharma PLC (AMYT) - 516,221 shares, 3.52% of the total portfolio. Shares added by 13.07%

Silverarc Capital Management, Llc initiated holding in Fulcrum Therapeutics Inc. The purchase prices were between $7.28 and $30.97, with an estimated average price of $18.95. The stock is now traded at around $18.070000. The impact to a portfolio due to this purchase was 2.96%. The holding were 185,691 shares as of 2021-09-30.

Silverarc Capital Management, Llc initiated holding in Arvinas Inc. The purchase prices were between $73.2 and $107.87, with an estimated average price of $88.21. The stock is now traded at around $82.515000. The impact to a portfolio due to this purchase was 1.73%. The holding were 37,249 shares as of 2021-09-30.

Silverarc Capital Management, Llc initiated holding in Leap Therapeutics Inc. The purchase prices were between $1.35 and $4.01, with an estimated average price of $1.87. The stock is now traded at around $2.405000. The impact to a portfolio due to this purchase was 1.41%. The holding were 620,000 shares as of 2021-09-30.

Silverarc Capital Management, Llc initiated holding in Erasca Inc. The purchase prices were between $17.43 and $24.34, with an estimated average price of $20.69. The stock is now traded at around $18.900000. The impact to a portfolio due to this purchase was 1.12%. The holding were 93,122 shares as of 2021-09-30.

Silverarc Capital Management, Llc initiated holding in Cytokinetics Inc. The purchase prices were between $18.54 and $35.74, with an estimated average price of $29.35. The stock is now traded at around $40.140000. The impact to a portfolio due to this purchase was 1%. The holding were 49,309 shares as of 2021-09-30.

Silverarc Capital Management, Llc initiated holding in Lucira Health Inc. The purchase prices were between $6.05 and $10.81, with an estimated average price of $8.41. The stock is now traded at around $6.550000. The impact to a portfolio due to this purchase was 0.95%. The holding were 220,758 shares as of 2021-09-30.

Silverarc Capital Management, Llc added to a holding in Cogent Biosciences Inc by 241.95%. The purchase prices were between $5.99 and $9.14, with an estimated average price of $7.68. The stock is now traded at around $10.575000. The impact to a portfolio due to this purchase was 2.28%. The holding were 677,900 shares as of 2021-09-30.

Silverarc Capital Management, Llc added to a holding in Cerus Corp by 3213.73%. The purchase prices were between $4.79 and $6.68, with an estimated average price of $5.84. The stock is now traded at around $7.090000. The impact to a portfolio due to this purchase was 2.07%. The holding were 619,369 shares as of 2021-09-30.

Silverarc Capital Management, Llc added to a holding in NextCure Inc by 152.65%. The purchase prices were between $6.74 and $8.02, with an estimated average price of $7.32. The stock is now traded at around $6.350000. The impact to a portfolio due to this purchase was 1.66%. The holding were 721,302 shares as of 2021-09-30.

Silverarc Capital Management, Llc added to a holding in Immatics NV by 51.30%. The purchase prices were between $11.58 and $15.46, with an estimated average price of $12.71. The stock is now traded at around $11.960000. The impact to a portfolio due to this purchase was 1.09%. The holding were 437,866 shares as of 2021-09-30.

Silverarc Capital Management, Llc added to a holding in Celldex Therapeutics Inc by 285.48%. The purchase prices were between $28.95 and $55.99, with an estimated average price of $46.84. The stock is now traded at around $43.520000. The impact to a portfolio due to this purchase was 0.87%. The holding were 38,243 shares as of 2021-09-30.

Silverarc Capital Management, Llc added to a holding in Seres Therapeutics Inc by 330.00%. The purchase prices were between $5.46 and $22.6, with an estimated average price of $9.91. The stock is now traded at around $7.865000. The impact to a portfolio due to this purchase was 0.83%. The holding were 274,833 shares as of 2021-09-30.

Silverarc Capital Management, Llc sold out a holding in Chinook Therapeutics Inc. The sale prices were between $11.5 and $14.86, with an estimated average price of $13.17.

Silverarc Capital Management, Llc sold out a holding in Macrogenics Inc. The sale prices were between $19.74 and $28.7, with an estimated average price of $24.13.

Silverarc Capital Management, Llc sold out a holding in Verastem Inc. The sale prices were between $2.54 and $4.07, with an estimated average price of $3.07.

Silverarc Capital Management, Llc sold out a holding in TCR2 Therapeutics Inc. The sale prices were between $8.44 and $18.35, with an estimated average price of $14.22.

Silverarc Capital Management, Llc sold out a holding in Aldeyra Therapeutics Inc. The sale prices were between $7.94 and $11.31, with an estimated average price of $9.2.

Silverarc Capital Management, Llc sold out a holding in Cullinan Oncology Inc. The sale prices were between $22.56 and $29.68, with an estimated average price of $26.76.

Silverarc Capital Management, Llc reduced to a holding in Dicerna Pharmaceuticals Inc by 86.5%. The sale prices were between $19.68 and $39.99, with an estimated average price of $27.67. The stock is now traded at around $21.345000. The impact to a portfolio due to this sale was -3.31%. Silverarc Capital Management, Llc still held 31,040 shares as of 2021-09-30.

Silverarc Capital Management, Llc reduced to a holding in Renalytix PLC by 70.67%. The sale prices were between $17.91 and $34.78, with an estimated average price of $25.82. The stock is now traded at around $21.545000. The impact to a portfolio due to this sale was -1.23%. Silverarc Capital Management, Llc still held 37,000 shares as of 2021-09-30.